Adage Capital Partners GP L.L.C. Cuts Stock Position in Compass Therapeutics, Inc. $CMPX

Key Points

• Adage Capital Partners GP L.L.C. reduced its position in Compass Therapeutics, Inc. by 33.7%, selling 2,019,810 shares, and now owns 3,975,000 shares valued at approximately $7.55 million.
• Several hedge funds increased their stakes in Compass Therapeutics, with Tower Research Capital LLC boosting its holdings by 298% during the last quarter.
• Analysts are optimistic about Compass Therapeutics, with a consensus rating of “Buy” and an average price target of $12.89, indicating potential for significant upside.

Adage Capital Partners GP L.L.C. cut its holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 33.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,975,000 shares of the company's stock after selling 2,019,810 shares during the quarter. Adage Capital Partners GP L.L.C. owned 2.87% of Compass Therapeutics worth $7,552,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in CMPX. Tower Research Capital LLC TRC lifted its holdings in shares of Compass Therapeutics by 298.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock valued at $25,000 after buying an additional 12,917 shares during the period. BNP Paribas Financial Markets bought a new position in shares of Compass Therapeutics during the 4th quarter valued at $27,000. Birchview Capital LP bought a new position in shares of Compass Therapeutics during the 1st quarter valued at $46,000. Squarepoint Ops LLC bought a new position in shares of Compass Therapeutics during the 4th quarter valued at $35,000. Finally, Walleye Trading LLC bought a new position in shares of Compass Therapeutics during the 1st quarter valued at $48,000. 68.43% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on CMPX shares. Raymond James Financial upgraded Compass Therapeutics to an "outperform" rating and set a $9.00 price objective for the company in a research note on Tuesday, July 1st. D. Boral Capital restated a "buy" rating and issued a $32.00 price objective on shares of Compass Therapeutics in a research note on Tuesday, August 12th. Finally, Guggenheim upped their price objective on Compass Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a research note on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating and nine have given a Buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $12.89.

Compass Therapeutics Stock Performance

Shares of CMPX stock opened at $3.44 on Monday. Compass Therapeutics, Inc. has a 52-week low of $1.27 and a 52-week high of $4.08. The firm has a market capitalization of $475.68 million, a PE ratio of -7.64 and a beta of 1.50. The stock has a fifty day simple moving average of $3.01 and a two-hundred day simple moving average of $2.47.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). On average, sell-side analysts forecast that Compass Therapeutics, Inc. will post -0.36 EPS for the current fiscal year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

Want to see what other hedge funds are holding CMPX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.